Clinical Trials
Clinical Trials
New Generation Pain Relief Without Opioids
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Opioids are highly effective at relieving both acute and chronic pain. However, this benefit comes at a significant cost: they are also highly addictive.
Ophthalmic End-to-End Drug Development Solutions
ISSUE NO. 29 — Building Your Early Phase Clinical Data, from Protocol to Regulatory Submission
Inside the Pharmacodynamic Toolbox: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-Active Drugs
ISSUE NO. 28 — Applications of Liquid-Filled Hard-Shell Capsules in Drug Development
Case Study― Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of Palovarotene (POS)
ISSUE NO. 27 — The Complexities of Early-Phase Ophthalmic Drug Development
ISSUE NO. 26 — CDISC Data Standards
The Clinical Data I
Five Reasons to Place Early-Phase Clinical Research in Canada
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
A well-planned clinical program designed to meet the regulatory requirements for the jurisdictions where you plan to request market authorization can be conduct
